LaFleur & Godfrey LLC boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.8% during the second quarter, Holdings Channel reports. The fund owned 204,521 shares of the medical equipment provider’s stock after buying an additional 3,559 shares during the period. Hologic comprises approximately 2.4% of LaFleur & Godfrey LLC’s investment portfolio, making the stock its 12th largest position. LaFleur & Godfrey LLC’s holdings in Hologic were worth $9,281,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Stratos Wealth Partners LTD. increased its position in shares of Hologic by 0.6% in the second quarter. Stratos Wealth Partners LTD. now owns 4,954 shares of the medical equipment provider’s stock valued at $225,000 after buying an additional 30 shares during the last quarter. Cleararc Capital Inc. increased its position in shares of Hologic by 1.1% in the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 77 shares during the last quarter. Compton Capital Management Inc. RI increased its position in shares of Hologic by 0.6% in the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock valued at $715,000 after buying an additional 100 shares during the last quarter. Advantus Capital Management Inc increased its position in shares of Hologic by 0.4% in the first quarter. Advantus Capital Management Inc now owns 27,936 shares of the medical equipment provider’s stock valued at $1,189,000 after buying an additional 116 shares during the last quarter. Finally, Shell Asset Management Co. increased its position in shares of Hologic by 0.7% in the first quarter. Shell Asset Management Co. now owns 24,647 shares of the medical equipment provider’s stock valued at $1,049,000 after buying an additional 182 shares during the last quarter. 94.46% of the stock is currently owned by institutional investors and hedge funds.

Hologic, Inc. (NASDAQ:HOLX) opened at 38.20 on Friday. Hologic, Inc. has a 1-year low of $35.15 and a 1-year high of $46.80. The stock has a market cap of $10.71 billion, a P/E ratio of 14.23 and a beta of 0.90. The firm’s 50-day moving average is $43.73 and its 200-day moving average is $42.89.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period last year, the company posted $0.51 earnings per share. On average, analysts forecast that Hologic, Inc. will post $2.01 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/hologic-inc-holx-position-raised-by-lafleur-godfrey-llc/1478558.html.

Several brokerages recently issued reports on HOLX. Stifel Nicolaus upped their price objective on shares of Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, May 11th. Jefferies Group LLC set a $49.00 price objective on shares of Hologic and gave the company a “buy” rating in a research note on Sunday, May 28th. Piper Jaffray Companies reissued a “buy” rating and set a $51.00 price objective on shares of Hologic in a research note on Friday, July 14th. Bank of America Corporation reissued a “neutral” rating and set a $48.00 price objective (up previously from $44.00) on shares of Hologic in a research note on Friday, July 21st. Finally, Barclays PLC reissued an “overweight” rating and set a $53.00 price objective (up previously from $50.00) on shares of Hologic in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company’s stock. Hologic presently has a consensus rating of “Buy” and a consensus price target of $48.64.

In related news, Director Lawrence M. Levy sold 9,076 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $42.80, for a total transaction of $388,452.80. Following the completion of the sale, the director now directly owns 43,165 shares in the company, valued at $1,847,462. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Peter J. Valenti III sold 10,005 shares of the firm’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total transaction of $434,617.20. Following the sale, the insider now owns 20,994 shares of the company’s stock, valued at $911,979.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 60,627 shares of company stock valued at $2,632,911. 0.79% of the stock is currently owned by corporate insiders.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.